retatrutide dosing phase 2 trial isn't a GLP-1. It's not a dual agonist. It's a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon simultaneously. Three receptors. Three mechanisms. One protocol. Swipe to see what Let's talk about a new

This process involves starting with a lower dose and gradually increasing it over several weeks or months until the target therapeutic dose is reached

It sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics

A 2022 randomized trial of exenatide did not meet its primary endpoint for reducing heavy drinking days in the overall population, though exploratory analyses suggested potential benefits in participants with obesity

CVOT trial will help determine if tirzepatide can demonstrate superior cardiovascular safety and potential additional cardiovascular benefits compared to the currently approved GLP-1RA dulaglutide